AUS
NZ
UK
CA
USA
IND
.jpg)
Highlights
- Canada Medical revenue increased during the fourth quarter of fiscal 2026.
- MTL Cannabis acquisition expanded production capacity and medical market presence.
- International cannabis revenue grew strongly with higher European demand.
Canopy Growth strengthened Canadian medical cannabis operations, expanded European business, and completed the MTL acquisition while remaining within the S&P/TSX Composite Index
Canopy Growth (TSX:WEED) operates in the cannabis sector, producing and distributing medical and adult-use cannabis products across Canada and selected international markets. The company is a constituent of the S&P/TSX Composite Index and remains one of Canada's established names among Cannabis Stocks. Recent developments included stronger fourth-quarter medical cannabis revenue, expanding international sales, and the completion of the MTL Cannabis acquisition, further strengthening the company's medical cannabis operations.
Medical cannabis operations expand
Medical cannabis remains a central business segment for the company, supplying registered patients through healthcare channels with dried flower, cannabis oils, softgels, capsules, and other regulated products.
During the fourth quarter of fiscal 2026, Canada Medical revenue increased compared with the corresponding period of the previous year. Continued patient demand, expanded product availability, and broader market reach contributed to segment performance.
Medical cannabis operations are supported through cultivation, manufacturing, product development, regulatory compliance, and distribution activities that serve patients across multiple provinces.
MTL Cannabis acquisition broadens footprint
The acquisition of MTL Cannabis represents an important addition to the company's Canadian operations. The transaction expands cultivation capacity, strengthens production capabilities, and broadens access to established medical cannabis customers, particularly within Quebec.
MTL Cannabis also contributes recognized cannabis brands and additional cultivation expertise, complementing existing production facilities and distribution networks.
Following completion of the acquisition, Canopy Growth (TSX:WEED) identified itself as Canada's largest medical cannabis company by revenue, reflecting the combined scale of medical cannabis operations.
International markets continue growing
International cannabis operations generated strong year-over-year growth during the latest quarter, supported primarily by expanding demand across European medical cannabis markets.
Germany continues representing one of the largest international destinations for medical cannabis exports. Regulatory developments have contributed to increasing patient access through pharmacies and healthcare providers, supporting higher shipment volumes from licensed producers.
The company also maintains commercial activities across additional international jurisdictions where medical cannabis frameworks permit regulated product distribution.
Broad cannabis product portfolio
The company develops cannabis products across multiple categories, including dried flower, pre-rolls, cannabis oils, beverages, edibles, vaporizers, and wellness products.
Its portfolio includes several established consumer and medical brands serving different market segments under Canada's regulated cannabis framework. Product development continues focusing on quality standards, manufacturing consistency, and compliance with applicable regulations.
Medical products are manufactured according to pharmaceutical-quality processes designed to meet domestic and international regulatory requirements.
Production and distribution capabilities
Cultivation and manufacturing operations support commercial activities through indoor growing facilities, processing centres, quality assurance laboratories, packaging operations, and distribution infrastructure.
Research and product development remain integrated with cultivation programs to improve product consistency, genetics, cannabinoid profiles, and manufacturing efficiency.
Distribution networks supply provincial wholesalers, authorized retailers, registered medical patients, and approved international healthcare markets.
Cannabis sector developments
Canada's regulated cannabis industry continues evolving through consolidation, product innovation, export expansion, and changing consumer preferences. Companies operating within the S&P/TSX Composite Index cannabis sector continue adapting production capacity, cultivation methods, and product portfolios to meet domestic and international demand.
Medical cannabis has become an increasingly important business segment as several international jurisdictions expand regulated patient access programs. European markets, particularly Germany, remain significant destinations for Canadian medical cannabis exports.
The sector also continues emphasizing regulatory compliance, product quality, manufacturing standards, and research supporting medical cannabis applications.
International presence supports operations
Canopy Growth (TSX:WEED) maintains commercial activities across Canada while expanding international medical cannabis distribution through regulated export markets. Operations include cultivation, product manufacturing, medical cannabis distribution, consumer cannabis products, and research activities supporting multiple product categories.
As a member of the S&P/TSX Composite Index, the company continues participating in Canada's regulated cannabis industry through domestic operations, international medical cannabis exports, and an expanding portfolio following the MTL Cannabis acquisition.
